Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Berti, Alvise; Yacoub, Mona‐Rita; Skov, Per Stahl; Falkencrone, Sidsel; Casati, Luca; Burastero, Samuele E.; Sabbadini, Maria Grazia; Colombo, Giovanni

doi:10.23822/eurannaci.1764-1489.17

Cited by 8 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinical response to omalizumab was the same in patients with a positive urticaria HR test compared to patients with a negative urticaria HR test. In a recent study by Berti et al ., similar observations were reported. However, a larger reduction in disease activity and a more frequent spontaneous disease remission at 12 months were reported by patients with a positive urticaria HR test.…”

Section: Discussionsupporting

confidence: 82%

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient‐reported outcomes: a prospective study

Ghazanfar

Holm

Thomsen

2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

Omalizumab is a highly effective therapy for antihistamine refractory CSU with treatment effects similar to those observed in randomized controlled trials. Validated PROs to assess disease activity, disease control and impairment of quality of life are valuable tools in the clinical management of CSU. Identification of patient-specific predictors of effect and safety of omalizumab in CSU is still warranted.

show abstract

Section: Discussionsupporting

confidence: 82%

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient‐reported outcomes: a prospective study

Ghazanfar

Holm

Thomsen

2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…This is the first description of French patient-control group of patients with CU, in the real life. The population we observed appeared to be very similar in age, higher frequency of females, frequent dermographism and overweight distribution as other populations described in other international [36,37,[41][42][43][44][45] or French [46,47] studies. The mean duration of the disease was quite long but this does not mean it was due to a delayed diagnosis as most of patients already have had 2 or 3 lines of treatment and were addressed to the local reference center because of difficulties in controlling the disease.…”

Section: Discussionsupporting

confidence: 82%

Two different Bioclinical profiles of Chronic Urticaria suggested by basophil number and Reactivity

Lambert¹

2021

J Clin Investig Dermatol

View full text Add to dashboard Cite

Chronic Urticaria (CU): is an heterogeneous disease supposed to be due to spontaneous release of histamine from unclarified activation of mast cell or basophil through IgE receptor pathway but treatment targeting either histamine or IgE are not always successful. The aim of this study was to explore Basophil phenotyping and functionality to better classify CU.Methods: the prospective, clinical study enrolled 31 CU and 29 age and sex matched controls. Basophils were analyzed by flow cytometry.Results and Discussion: Our CU population demography was very similar to cohorts previously reported. CU were active for 5.58+5.4 years and severe (UAS7 = 25.8+10). Serum IgE were higher than 114kU/L in 36.8% CU vs 12.0% HC. Serum tryptase was higher than 7µg/L in 20%. Basophil represented less than 0.1% of leukocytes in 32.3% CU and even more in case of recent flares. Ex vivo basophil activation was defective in 75.9% of CU vs 31% of HC. However despite an active disease, 41.9% of patients kept a high basophil count and 7 (24.1%) a high reactivity with low serum tryptase and low activation profile suggesting their basophils are not the main effector in the diseases. Conclusions:Monitoring Basophil count and ex vivo reactivity together with the level of IgE should help in suspecting the basophil and IgE involvement or alternative mechanisms of CU. This could lead to a classification of CU in its heterogeneity and help predicting its response to anti-histaminic or anti-IgE therapies.

show abstract

“…We could not compare data with autologous serum or plasma skin tests (ASST and APST), as these are not routinely performed in our country. According to the findings of Berti et al, there does not seem to be any association between in vivo and in vitro tests in patients with CU (19), and the same could be true for AE. The performance of ASST and APST would be desirable to study in the future, to confirm these findings also in mono-symptomatic AE.…”

Section: Resultsmentioning

confidence: 92%

Histamine-release test in angioedema patients without urticaria - a retro-spective cohort study of 404 patients

Authried

Prasad

Rasmussen

et al. 2018

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

A subset of patients with angioedema (AE) and urticaria has histamine releasing autoantibodies. The histamine release test (HR-test) has been used as a tool in chronic urticaria to define the autoimmune subgroup and may possibly guide the clinician to a more personalized therapy, like omalizumab and cyclosporine. The prevalence and value of positive histamine releasing autoantibodies in monosymptomatic AE is sparsely described in the literature. The purpose of this study was to report the prevalence of positive histamine releasing autoantibodies in a cohort of patients with recurrent AE and evaluate the usefulness of this test in AE patients. We performed a retrospective cohort study of 612 patients referred due to AE between 1995 and 2013. HR-test results were available in 404 patients. In the sub-group of patients with AE and urticaria, 17.3% had a positive HR-test but only 4.3% of patients with mono-symptomatic AE had a positive HR-test. No statistically significant treatment benefits of antihistamines, corticosteroids or adrenaline were found comparing patients with angioedema +/- urticaria based on the result of the HR-test (negative / positive). Thus, the HR-test result cannot be used as predictor of the efficacy of anti-allergic treatment.

show abstract

Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Abstract: Summary Background. Histamine release (HR) test has previously been shown to predict the presence of endogenous histamine-releasing factors in chronic spontaneous urticaria (CSU

Cited by 8 publications

References 17 publications

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient‐reported outcomes: a prospective study

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient‐reported outcomes: a prospective study

Two different Bioclinical profiles of Chronic Urticaria suggested by basophil number and Reactivity

Histamine-release test in angioedema patients without urticaria - a retro-spective cohort study of 404 patients

Contact Info

Product

Resources

About